GlassScriptPhysician profile
Felicity M Warren
NPI 1295727527
$3,837.62
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,663 · 2020: $512 · 2021: $639 · 2022: $1,024.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,156.38 | 2019-2022 | |
| Ucb, INC. | $612.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $505.89 | 2019-2022 | |
| Pfizer INC. | $440.13 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $206.50 | 2019-2020 | |
| Journey Medical Corporation | $162.44 | 2019-2022 | |
| Almirall LLC | $128.72 | 2019-2022 | |
| Lilly USA, LLC | $122.33 | 2019-2022 | |
| Incyte Corporation | $112.73 | 2022 | |
| Merz North America, INC. | $64.57 | 2019 | |
| Organogenesis INC. | $56.86 | 2021 | |
| Janssen Biotech, INC. | $56.59 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $40.33 | 2020-2021 | |
| Amgen INC. | $38.49 | 2020-2021 | |
| Leo Pharma INC. | $32.46 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Promius Pharma LLC | $26.01 | 2019 | |
| Merck Sharp & Dohme LLC | $19.27 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.52 | 2020 | |
| Dermavant Sciences, INC. | $14.00 | 2022 | |
| Sandoz INC. | $13.99 | 2020 | |
| Galderma Laboratories, L.P. | $12.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felicity Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.